Paul Hudson, Sanofi CEO (Jeremy Paoloni/Abaca/Sipa USA(Sipa via AP Images))
May 21, 2024 09:58 AM EDTUpdated May 24, 01:57 PM
Deals
R&D
AI

Sanofi, Ope­nAI, For­ma­tion Bio an­nounce AI drug de­vel­op­ment part­ner­ship

Andrew Dunn

Senior Biopharma Correspondent

French phar­ma­ceu­ti­cal gi­ant Sanofi will work with the tech pow­er­house Ope­nAI and New York-based start­up For­ma­tion Bio to de­vel­op AI-pow­ered soft­ware in drug R&D, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times